141 related articles for article (PubMed ID: 29958626)
1. Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.
Zhao B; Zhao H; Zhao J
Crit Rev Oncol Hematol; 2018 Aug; 128():110-117. PubMed ID: 29958626
[TBL] [Abstract][Full Text] [Related]
2. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
Wu Y; Wang Q; Zhang J; Cao J; Wang B; Hu X
Support Care Cancer; 2020 Aug; 28(8):3819-3829. PubMed ID: 31832821
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
Vahdat LT; Garcia AA; Vogel C; Pellegrino C; Lindquist DL; Iannotti N; Gopalakrishna P; Sparano JA
Breast Cancer Res Treat; 2013 Jul; 140(2):341-51. PubMed ID: 23877339
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Tsurutani J; Sakata Y; Matsuoka T
Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Lück HJ; Schmidt M; Hesse T; Hoffmann O; Heinrich BJ; Park-Simon TW; Grischke EM; Weide R; Müller-Huesmann H; Lüdtke-Heckenkamp K; Fischer D; Zemlin C; Kögel M; Wu J; Schmitz H; Engelbrecht C; Jackisch C
Oncologist; 2023 Dec; 28(12):e1152-e1159. PubMed ID: 37555463
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
12. Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.
Peng L; Hong Y; Ye X; Shi P; Zhang J; Wang Y; Zhao Q
Oncotarget; 2017 Dec; 8(67):112076-112084. PubMed ID: 29340112
[TBL] [Abstract][Full Text] [Related]
13. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
14. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
Goodin S; Barbour S; Song J; Berrak E; Cox D
Am J Health Syst Pharm; 2015 Dec; 72(24):2150-6. PubMed ID: 26637514
[TBL] [Abstract][Full Text] [Related]
17. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Acta Oncol; 2015 Apr; 54(4):522-9. PubMed ID: 25383448
[TBL] [Abstract][Full Text] [Related]
18. Clinical and preclinical features of eribulin-related peripheral neuropathy.
Tarasiuk O; Cavaletti G; Meregalli C
Exp Neurol; 2022 Feb; 348():113925. PubMed ID: 34801586
[TBL] [Abstract][Full Text] [Related]
19. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
Wozniak KM; Wu Y; Farah MH; Littlefield BA; Nomoto K; Slusher BS
Neurotox Res; 2013 Oct; 24(3):338-44. PubMed ID: 23637052
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
